Observational studyInterventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences2020
Endovascular treatment of cerebral dural arteriovenous fistulas with SQUID 12.
Observational study in Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Safety and efficacy of newer liquid embolic agents Squid and PHIL in endovascular embolization of cerebral arteriovenous malformations and dural arteriovenous fistulas: A systematic review and meta-analysis.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2026Pooled it
- Traumatic middle meningeal arteriovenous fistulas (MMAVFs): an exploratory systematic review.Neurosurgical review · 2024Pooled it
- Plug-and-Push Embolisation of a Tentorial Dural Arteriovenous Fistula Using Squid-18 and Squid-12.Cureus · 2026Article
- Transvenous curative embolization of brain arteriovenous malformations using extra-low viscosityInterventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025Article
- Penetration of Non-Adhesive Gel-like Embolic Materials During Dural Vessels Embolization According to Characteristics of Tantalum Powder.Journal of functional biomaterials · 2024Article
- Endovascular treatment of intracranial dural arteriovenous fistulas with Onyx: A consecutive series of 62 patients from a single-center.The neuroradiology journal · 2024Article
- Preoperative Direct Puncture Embolization of Castleman Disease of the Parotid Gland: A Case Report.Current oncology (Toronto, Ont.) · 2024Article
- LIQUID - Treatment of high-grade dural arteriovenous fistulas with Squid liquid embolic agent: a prospective, observational multicenter study.Journal of neurointerventional surgery · 2023Observational
- Embolization of brain arteriovenous malformations with squid co-polymer embolic material: Initial experience.Journal of interventional medicine · 2023Article
- Liquid Embolic Agents for Endovascular Embolization: A Review.Gels (Basel, Switzerland) · 2023Review
- Middle Meningeal Artery Embolization for the Management of Chronic Subdural Hematomas: A New-Old Treatment.Acta neurochirurgica. Supplement · 2023Article
- Glue, Onyx, Squid or PHIL? Liquid Embolic Agents for the Embolization of Cerebral Arteriovenous Malformations and Dural Arteriovenous Fistulas.Clinical neuroradiology · 2022Review
- The Common but Complicated Tool: Review of Embolic Materials for the Interventional Radiologist.Seminars in interventional radiology · 2021Review
- Visceral Artery Aneurysms Embolization and Other Interventional Options: State of the Art and New Perspectives.Journal of clinical medicine · 2021Review
- Facial palsy after embolization with Squid® 12.BMC neurology · 2021Article
- Emergency tips recanalisation and gastroesophageal varices embolisation with an ethylene vinyl alcohol copolymer agent (Squid) and detachable coils.European radiology experimental · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndovascular therapy with liquid embolic agents (LEAs) is the gold standard for the treatment of cerebral dural arteriovenous fistulas (cDAVFs). The aim of the study is to retrospectively evaluate effectiveness, safety, and midterm follow-up results of endovascular treatment of cDAVFs using SQUID 12.
methodsBetween June 2017 and January 2020 the authors retrospectively reviewed clinical, demographic and embolization data of 19 consecutive patients with cDAVF who underwent embolization using SQUID 12. The number of arteries catheterized for each procedure, the total amount of embolic agent, the occlusion rate, the injection time, any technical and/or clinical complications were recorded. Mid-term follow-up with DSA was reviewed.
results20 procedures were performed in 19 patients. A transarterial approach was accomplished in 19 procedure; a combined transvenous-transarterial approach was realized in 1 treatment. The average time of injection was 33 minutes (2-82 minutes), and the average amount of SQUID 12 was 2.8 mL (0.5-6 mL). Complete angiographic cure at the end of the procedure was achieved in 17 patients. No major periprocedural adverse events were recorded. Mid-term follow-up was achieved in 15 out of 19 patients and confirmed complete occlusion of the cDAVFs in 13/15 patients (87%); in 2 of the initially cured patients a small relapse was detected.
conclusionsThe treatment of the cDAVFs using SQUID 12 was effective and safe. The lower viscosity seems to allow an easier penetration of the agent with a high rate of complete occlusion of the cDAVFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.